What are the key outcomes of the PROGRESS Collaborative Group's randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack?
The PROGRESS Collaborative Group's randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack found that the regimen led to a significant reduction in the risk of major vascular events, including stroke, myocardial infarction, and vascular death, compared to placebo. This suggests that this regimen can be effective for reducing the risk of recurrent stroke and other major vascular events in individuals with a history of stroke or transient ischemic attack.